Evidence map›Paper›PMID 24715522›Full record

ArticleInternational journal of hematology2014

Incidence and outcomes of Clostridium difficile-associated disease in hematopoietic cell transplant recipients.

Achuta Kumar Guddati, Gagan Kumar, Shahryar Ahmed, Muhammad Ali, Nilay Kumar, Parameswaran Hari, Nanda Venu

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Derivation and validation of a prediction model for primary and recurrentAntimicrobial stewardship & healthcare epidemiology : ASHE · 2026
    Article
  6. Management ofEClinicalMedicine · 2025
    Review
  7. Clinical microbiology reviews · 2024
    Review
  8. Minimizing the risk ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2023
    Article
  9. Risk Factors and Outcome ofJournal of clinical medicine · 2020
    Article
  10. Article
  11. Review
  12. Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Article
  13. Incidence Rates and Risk Factors ofOpen forum infectious diseases · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Clostridium difficile.Clinics in laboratory medicine · 2010
    Review
  18. Article
  19. Pre-transplantCell transplantation
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Achuta Kumar GuddatiDivision of Internal Medicine, Massachusetts General Hospital, Harvard Medical School, 50 Fruit Street, Boston, MA, USA, aguddati@partners.org.
Gagan Kumar
Shahryar Ahmed
Muhammad Ali
Nilay Kumar
Parameswaran Hari
Nanda Venu
Medical College of Wisconsin · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematopoietic stem cell transplant (HSCT) recipients are at a high risk of Clostridium difficile-associated disease (CDAD) given frequent hospitalizations, prolonged antibiotic usage and altered integrity of intestinal mucosa. The prevalence and trends of CDAD in HSCT patients have not been extensively studied. In this study, the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes were used to identify CDAD in HSCT patients using a nationwide inpatient sample in the United States from 2000 to 2009. The prevalence of CDAD and in-hospital mortality in HSCT were investigated and compared to those without any transplants. Multivariate analysis was performed to identify if BMT and graft versus host disease (GVHD) were independently associated with mortality in CDAD patients. Of the 344,507 HSCT discharges, 4.7 % had CDAD. This was about 5 times higher when compared to non-transplant discharges. During engraftment admission, rates of CDAD were higher in allogenic group (8.4 vs. 5.7 %, p < 0.001). In subsequent admissions, those with GVHD had higher rates of CDAD (5.7 vs. 3.2 %, p < 0.001). On adjusted analysis in patients with CDAD, during engraftment admission, allogenic group had significantly higher mortality when compared with non-transplants (OR 3.7). Notably, there was no significant difference in mortality between patients with and without CDAD during the engraftment period for the allogeneic group. In subsequent admissions, there was higher mortality in those with GVHD (OR 4.8). Though the prevalence of CDAD in non-transplant population doubled (from 0.44 % in 2000 to 0.99 % in 2008), it has remained stable in HSCT patients (from 4.8 % in 2000 to 5.6 % in 2008). HSCT and GVHD are independently associated with CDAD though its presence does not affect mortality.

Indexed as

Clostridioides difficileAdolescentAdultAgedAged, 80 and overComorbidityCross InfectionEnterocolitis, PseudomembranousFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHospitalizationHumansIncidenceMaleMiddle Aged

Identifiers

PMID24715522
OpenAlexW2006804678

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.